Mr. John HODGSON (Director, Critical I Limited) 

“How chronic underfunding affects economic competitiveness of European life sciences - The Second Critical I report”.  

Mr. Bart Van Looy (K.U. Leuven Research & Development) 

“The comparison of the patenting system in Europe and in the rest of the world: an indication for the future”. 
 Questions & Answers session
 

15:00 – 16.00


                Industry Leaders Panel “Starting from here: can European biotech make 10 years progress in the next decade?”
            Panel discussion with EuropaBio President and Council Chair

16.00 – 16.30  Coffee break

16.30 – 17.00

Mr. John HOLLOWAY (Director Investments, EIF – European Investment Fund) 
“How private investors with government support can produce biotechnology winners?”
Questions & Answers session

17.00 – 17.30

Mr. Michael GRIFFITH (Chair of EPPOSI – European Platform for Patients Organisations, Science and Industry) 
“Learning from rare diseases: the potential for change” 
Questions & Answers session
Questions & Answers session

17.30 – 18.00

Lord Dick TAVERNE  
“Why the EU must not reject genetic modification”  
Questions & Answers session
Questions & Answers session

18.00 – 18.30

Mr. Iain GILLESPIE (Head of the Biotechnology Division, OECD) 
“Can bioscience underpin economic strategies?”  
Questions & Answers session

Questions & Answers sessi

18:30 - 18:35

               Prof. Louis Vertegaal (Directeur Chemistry Division, NWO)  
           "Announcement ERA - Net Industrial Biotech"  

18.35 – 18.50

              Conclusions
usions  Dr. Johan VANHEMELRIJCK (Secretary General, EuropaBio)